Novo Nordisk and Sandoz settle Victoza patent suit

Novo Nordisk and Sandoz have settled an ongoing patent dispute over the blockbuster diabetes treatment Victoza (Liraglutide) before the companies were meant to face trial in April.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Novo Nordisk makes $1.1bn bid for biopharma company

2 September 2022 Massachusetts-based target company specialises in rare blood disorders | Deal gives Novo Nordisk access to lead development candidate, etavopivat.

Generics

Novo Nordisk seeks to block Mylan generic

22 August 2019 Danish pharmaceutical company Novo Nordisk has sued Mylan in a US court over a proposed generic of diabetes drug Victoza (liraglutide).

Americas

Teva enters settlement with Novo Nordisk to sell Victoza generic

19 March 2019 Danish pharmaceutical company Novo Nordisk and generics maker Teva have reached a settlement in their US dispute over Victoza.

More on this story

Americas

Novo Nordisk makes $1.1bn bid for biopharma company

2 September 2022 Massachusetts-based target company specialises in rare blood disorders | Deal gives Novo Nordisk access to lead development candidate, etavopivat.

Generics

Novo Nordisk seeks to block Mylan generic

22 August 2019 Danish pharmaceutical company Novo Nordisk has sued Mylan in a US court over a proposed generic of diabetes drug Victoza (liraglutide).

Americas

Teva enters settlement with Novo Nordisk to sell Victoza generic

19 March 2019 Danish pharmaceutical company Novo Nordisk and generics maker Teva have reached a settlement in their US dispute over Victoza.

More on this story

Americas

Novo Nordisk makes $1.1bn bid for biopharma company

2 September 2022 Massachusetts-based target company specialises in rare blood disorders | Deal gives Novo Nordisk access to lead development candidate, etavopivat.

Generics

Novo Nordisk seeks to block Mylan generic

22 August 2019 Danish pharmaceutical company Novo Nordisk has sued Mylan in a US court over a proposed generic of diabetes drug Victoza (liraglutide).

Americas

Teva enters settlement with Novo Nordisk to sell Victoza generic

19 March 2019 Danish pharmaceutical company Novo Nordisk and generics maker Teva have reached a settlement in their US dispute over Victoza.